ARQT — ARCUTIS BIOTHERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying ARQT?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 4 tracked investors who changed their ARQT position last quarter, 2 bought and 2 sold (50% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime). 1 congressional purchase, 0 sales disclosed in the last 6 months.
- +2 tracked investors added or increased positions last quarter (Izzy Englander, Ken Griffin)
- +3 tracked investors reported holding ARQT at their latest filing
- −2 tracked investors reduced or exited last quarter (1 reduced, 1 sold out)
- −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.
About ARCUTIS BIOTHERAPEUTICS INC (ARQT)
ARCUTIS BIOTHERAPEUTICS INC (ARQT) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $43M. Across recent filings, tracked investors recorded 8 new positions, 15 increased, 6 reduced, and 6 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ARQT
How many top investors track ARQT
A small number of top investors own this.
ARQT Ownership Composition
How ARCUTIS BIOTHERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant99.4%
- Macro0.6%
Tracked investors currently reporting ARQT
1 tracked investor has since exited this position — listed separately below.
- Ken GriffinSep 30, 2026Citadel AdvisorsShares1.6MValue$42.9M% Portfolio0.00%
- Izzy EnglanderSep 30, 2026Millennium ManagementShares919.4KValue$24.3M% Portfolio0.01%
- Paul Tudor JonesSep 30, 2026Tudor Investment CorpShares15.4KValue$405.9K% Portfolio0.00%
Previously held ARQT
These investors reported ARQT in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Steve Cohen | Point72 Asset Management | 362.4K | $9.5M | Jun 30, 2026 |
Recent activity
- Reduced$405.9K(-88.36%)Nov 16, 2026
- Increased$24.3M(62.99%)Nov 16, 2026
- Sold$0(-100.00%)Nov 16, 2026
- Increased$42.9M(27.92%)Nov 16, 2026
- Increased$10.7M(123.81%)Nov 14, 2024
- Increased$32.2M(101.33%)Feb 14, 2025
- Reduced$7.4M(-79.50%)May 15, 2025
- Increased$12.8M(92.31%)Aug 14, 2025
- Increased$6.9M(57.74%)Feb 17, 2026
- Reduced$1.2M(-79.16%)May 15, 2026
- Increased$14.8M(1043.40%)Aug 14, 2026
- Increased$29.3M(3.95%)Nov 14, 2024
- Increased$6.9M(146.58%)May 15, 2025
- Reduced$3.8M(-38.31%)Aug 14, 2025
- Sold$0(-100.00%)Nov 14, 2025
- Increased$33.3M(1191.79%)Aug 14, 2026
- New$2.3MNov 14, 2024
- Increased$24.4M(617.52%)Feb 14, 2025
- Reduced$13M(-52.64%)Jul 21, 2025
- Increased$20.8M(78.86%)Aug 14, 2025
- Sold$0(-100.00%)Nov 14, 2025
- New$12.3MFeb 17, 2026
- Increased$13.9M(38.98%)May 15, 2026
- Reduced$9.5M(-38.66%)Aug 14, 2026
- Sold$0(-100.00%)Aug 14, 2024
- $195KNov 14, 2024
- Increased$896.2K(206.88%)Feb 14, 2025
- Increased$1.6M(60.68%)May 15, 2025
- Sold$0(-100.00%)Aug 14, 2025
- $1.3MDec 9, 2025
- Sold$0(-100.00%)May 15, 2026
- $3.5MAug 14, 2026
- New$28.2MAug 14, 2024
- $3.8MMay 15, 2024
- $2MMay 15, 2024
Frequently asked questions
- How many institutional investors hold ARQT?
- 3 tracked institutional investors disclosed a position in ARQT (ARCUTIS BIOTHERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ARQT?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ARQT, valued at $43M.
- Did institutional ownership of ARQT increase or decrease?
- Across recent 13F filings, tracked investors recorded 8 new positions, 15 increased, 6 reduced, and 6 fully exited ARQT.
- Where does this ARQT ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.